Note 2 – Going Concern Uncertainty

To date, the Company has generated minimal revenues, experienced negative operating cash flows and has incurred substantial operating losses from its activities. Management expects the Company to continue to generate substantial operating losses and to continue to fund its operations primarily through utilization of its current financial resources, future product sales, and through the issuance of debt or equity, as well as through other strategic alternative transactions. Rising inflation, rising interest rates, and financial market volatility may adversely impact the Company’s ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing initiatives. The uncertain financial markets, potential disruptions in supply chains, and changing priorities could also affect the Company’s ability to enter into key agreements. These disruptions may negatively impact the Company’s sales, its results of operations, financial condition, and liquidity into 2024.

We have generated limited revenues to date from the sale of products. We have never been profitable and have incurred significant net losses each year since our inception, including a loss of $12.9 million for the year ended December 31, 2023, and we expect to continue to incur net operating losses for the foreseeable future. As of December 31, 2023, we had $5.0 million in cash and cash equivalents and an accumulated deficit of $154.2 million. We expect our current spend level to continue in connection with ongoing operating activities, including expenditures in R&D, sales and marketing, clinical affairs and manufacturing. In order to continue to operate as a standalone company, we will need additional financing to support our continuing operations. We also have significant debt under our Loan Agreement with Kreos which could negatively impact our ability to operate or consummate a strategic transaction.

In addition, we are exploring a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. If a strategic transaction is not completed, or if additional financing is not available, we may not be able to service our outstanding indebtedness and our payables and may have to file for bankruptcy protection or pursue a dissolution of the Company and liquidation of all of our remaining assets. In such an event, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations and service our outstanding indebtedness. We cannot provide assurance as to the amount of cash that will be available to distribute to stockholders, if any, after paying our debts and other obligations and setting aside funds for reserves, nor as to the timing of any such distribution, if any.

Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments that might result from the outcome for his uncertainty.